Biovaxys Technology Corp
F:5LB0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biovaxys Technology Corp
F:5LB0
|
CA |
|
Bank of Ireland Group PLC
F:BIRB
|
IE |
|
D
|
DAVIDsTEA Inc
F:DAT
|
CA |
Intrinsic Value
The intrinsic value of Biovaxys Technology Corp (5LB0) under the Base Case is 0.126 EUR per share. Compared with the current market price of 0.029 EUR, the stock appears Undervalued by 77% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Biovaxys Technology Does
BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-11-21. The firm is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergies, and other immunological diseases.
- Headquarters
- Canada CA
- IPO date
- Nov 21, 2018
Earnings Waterfall
Biovaxys Technology Corp
The intrinsic value for Biovaxys Technology Corp (5LB0) under the Base Case is 0.126 EUR.
Compared with the current market price of 0.029 EUR, the stock appears Undervalued by 77% .